Antaros Medical is proud to have contributed to MAGMA’s special issue on “Magnetic resonance imaging biomarkers of renal disease” published this month (https://link.springer.com/journal/10334/33/1 ). This special issue was co-ordinated by the PARENCHIMA network for Renal Imaging (https://www.renalmri.org/), a COST Action supported by European Cooperation in Science and Technology.
Paul Hockings is Senior Imaging Director at Antaros Medical, and Adjunct Professor at MedTech West, Chalmers University of Technology, and a member of the PARENCHIMA management committee. He contributed as a guest editor on the special edition, and as a co-author on the review “Consensus‑based technical recommendations for clinical translation of renal T1 and T2 mapping MRI” by Dekkers, et al.
There is a huge unmet need for improved biomarkers within renal disease. Magnetic Resonance Imaging (MRI) is a promising non-invasive biomarker both for the understanding of renal function and pathophysiology. The PARENCHIMA collaboration is one important initiative coordinating the research of leading European groups in this area to:
- Improve the reproducibility and standardisation of renal MRI biomarkers
- Increase their availability by developing on an open-access toolbox with software and data
- Demonstrate biological validity and clinical utility in a prospective multicentre clinical study.
Antaros is already using MRI in clinical trials of new medicines for renal disease and is very glad to be able to contribute to this very important field in order to enable pharmaceutical companies to develop new medicines to help kidney patients.
Link to The MAGMA’s special issue on “Magnetic resonance imaging biomarkers of renal disease”
Link to editorial “Special issue on magnetic resonance imaging biomarkers of renal disease”
Link to review article “Consensus-based technical recommendations for clinical translation of renal T1 and T2 mapping MRI”